Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer
Study now open for enrollment at leading academic medical centers CARY, N.C. and BRADENTON, Fla., May 20, 2026 /PRNewswire/ -- Continuity Biosciences, LLC, a clinical-stage biotechnology company advancing precision drug delivery platforms, today...
Be Where The Next Now of Retail Unfolds: NRF 2026 APAC Unveils Star Speakers, Bigger Expo and Limited-Time Travel Incentives
SINGAPORE, April 21, 2026 /PRNewswire/ -- With momentum building rapidly, NRF 2026: Retail's Big Show Asia Pacific (NRF 2026 APAC), co-organised by the National Retail Federation (NRF) and Comexposium Singapore, is bringing together the region's...
Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501
Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilico received an additional milestone payment of USD 5 million from Menarini Group after first-in-patient dosing in a Phase 1 trial of MEN2501, highly...
Trip.com Group's 2026 Lunar New Year Forecast: Longer Journeys and Premium Travel Gain Momentum in the Year of the Horse
Travellers are taking longer trips and venturing further, with cross-border stays of seven nights or more up nearly 40% and long-haul bookings up over 50%. Comfort is becoming a priority, with first-class and business-class flights and five-star...
LG Display showcases wide lineup of world-first, leading OLED monitors
SEOUL, South Korea, Dec. 28, 2025 /PRNewswire/ -- LG Display, the world's leading innovator of display technologies, is set to rewrite industry records once again at CES 2026, the world's largest IT and consumer electronics exhibition. LG Display's...
Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial
Preclinical Results Demonstrate Complete Response and Tumor Regression in ACC PDX Models SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ -- Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation,...
CGTN: Hainan Free Trade Port: A key gateway for China's high-level opening up
A month before the official launch of China's Hainan Free Trade Port island-wide special customs operations on December 18, CGTN published an article explaining what the new customs operations mean. It highlights this landmark step as a key...
The 138th Canton Fair Boosts Global Exposure for Specialized Materials and Chemical Products
GUANGZHOU, China, Oct. 29, 2025 /PRNewswire/ -- The 138th Canton Fair is drawing attention to the rapidly advancing field of new materials and chemical products. This highly specialized exhibition section attracts buyers with clear objectives who...
Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs Promising antitumor activity was observed in heavily...
Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241
PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical needs in non-small cell lung cancer ("NSCLC") CASTRES, France, June 16, 2025 /PRNewswire/ --...